学生汇报专场，汇报人：张禹洋、张想、李冉

时间：2025年4月11日（周五）13:30-15:00

地点：北大国发院承泽园344教室

主持人： 雷晓燕、易君健

参与老师：张丹丹、李玲、刘国恩、黄炜

汇报人1：张禹洋 （22级博士，导师：刘国恩）

题目：《The Dual Impact of Teledoctor: Direct and Spillover Effects on Offline Medical Service Provision》

摘要： 

互联网 + 医疗是新形势下中国国民健康体系的全新生产形式，为医疗领域注入了数字经济要素。本文立足于线上互联网医生注册数据和线下病案数据，选择 2013-2023 年作为研究区间，检验了医生注册成为互联网医生对线下医疗服务提供的直接和溢出影响。在控制了时间和个体固定效应后，本文发现注册成为互联网医生能够提升医生服务的质量和数量，且存在正向的溢出效应。这一结果为进一步推广在线医疗提供了政策依据

汇报人2：张想 （21级博士生，导师：李玲）

题目：《问诊大数据分析“双减”政策对学生心理健康的影响》

摘要：

本文利用4年内全国各地数百万次精神科线上问诊记录，对我国2021年推行的“双减”政策进行了评估。因果识别首先表明，我国中小学教育可使学生出现精神问题的风险升高约40%，且教育发达地区学生在开学后出现精神问题的风险更大，并随年级升高而不断加重。而在“双减”政策推行后，试点地区青少年儿童在开学后出现精神问题的风险立即出现了下降，其降幅近80%；在政策计划的三年内，全国所有地区青少年儿童心理健康均实现了改善。此外，对于此前学生更容易出现精神问题的应试成绩较好、人均收入较高地区，“双减”政策的减负效果更佳。

汇报人3：李冉 （22级博士，导师：刘国恩）

题目：《The Puzzle of Positive Drug Price Elasticity: The Role of Brand Preferences》

摘要：

The rapid increase in pharmaceutical expenditures poses a global policy challenge. While price reductions through insurance coverage, regulations, or procurement reforms are generally believed to enhance affordability and patient welfare, they may have unintended consequences. This study examines China's centralized drug procurement program, which transitioned from decentralized purchasing to competitive bidding in nine provinces. The program effectively lowered drug prices but paradoxically led to reduced utilization of chronic condition drugs among patients with brand preferences. Using a difference-in-differences framework, the study analyzes patient records from Beijing community healthcare centers and finds that patients with brand preferences significantly decreased their purchases of price-reduced drugs post-policy. This effect contrasts with increased engagement and purchases by patients without brand preferences. The findings highlight the trade-offs between cost savings and choice distortion, emphasizing the need to consider non-price attributes like brand preference in policy design. They also reveal the dual effects of generic drug entry on consumer welfare, suggesting that while price reductions can improve affordability, they may suppress utilization due to preference mismatches. These insights offer guidance for refining procurement designs, health insurance strategies, and patent policies to balance affordability with patient-centered care.